Merck: Q4 earnings in line with expectations.

(CercleFinance.com) - Merck has reported Q4 2016 adjusted net earnings that are down by about 5% to just under 2.
5 billion dollars, or 89 cents per share, in line with the consensus.

The Kenilworth, New Jersey-based Healthcare group reported sales that are down 1% at 10.1 billion dollars, with this figure only down due to a negative FX effect.

At constant exchange rates, the 1% decline in pharmaceutical revenues - which particularly suffered from the by the Zetia/Vytorin anti-cholesterol franchise (-13%) - were offset by growth in animal health (+7%) and other income (+30%).

Copyright (c) 2017 CercleFinance.com. All rights reserved.